Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant human papillomavirus bivalent vaccine

View Patient Information
A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant human papillomavirus bivalent vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
US brand name:Cervarix
Foreign brand name:Cervarix
Abbreviation:HPV 16/18 L1 VLP/AS04 VAC
Code name:GSK-580299
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search